Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
The Company’s portfolio of Phase 3 product candidates are:
- Remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD) in children
- Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection
- REVASCOR® for advanced chronic heart failure
- MPC-06-ID for chronic low back pain due to degenerative disc disease
The Company also has a promising emerging pipeline and next generation technologies.
Innovative technology platform
Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.
Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblast’s cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression.
Events
August 2023
Financial Results and Operational Update for the Period Ended June 30, 2023
August 2023
Corporate Update – Update on BLA for Graft Versus Host Disease
May 2023
Operational Highlights and Financial Results for the Period Ended March 31, 2023
February 2023
Operational Highlights and Financial Results for the Period Ended December 31, 2022
November 2022
Operational Highlights and Financial Results for the Period Ended September 30, 2022
November 23 (AEDT); November 22 (EST)
2022 Mesoblast Limited Annual General Meeting
Latest News
31 August 2023
MSB Annual Financial Results and Operational Update >
31 August 2023
Annual Financial Results Presentation >
31 August 2023
Preliminary Final Report including Appendix 4E >
29 August 2023
Mesoblast 2023 Full Year Financial Results Webcast >
29 August 2023
Change in substantial holding >